MedTrace Logo

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

NCT00660543 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-05-16

Study results available
· View outcomes & findings →

Summary

This pilot clinical trial studies how a magnetic resonance imaging (MRI) study with ferumoxytol works as a contrasting agent in assessing early response in patients with glioblastoma multiforme receiving temozolomide and radiation therapy. Ferumoxytol is a very small form of iron particles that are injected into the body and taken up by certain tissues which may make these tissues easier to see during imaging. Diagnostic procedures, such as an MRI study with ferumoxytol, may help measure a patient's response to earlier treatment.

Conditions

  • Adult Brain Glioblastoma

Interventions

DRUG

Gadolinium

Given IV

DRUG

Ferumoxytol Non-Stoichiometric Magnetite

Given IV

OTHER

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Undergo DCE MRI

OTHER

Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging

Undergo DSC MRI

OTHER

Diffusion Weighted Imaging

Undergo DWI

OTHER

MRI-Based Angiogram

Undergo TOF MR angiography

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • OHSU Knight Cancer Institute

    lead OTHER

Principal Investigators

  • Edward Neuwelt · OHSU Knight Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00660543 on ClinicalTrials.gov